Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

被引：0
|
作者：
Greenberg, Arthur [1 ]
机构：
[1] Duke Univ, Dept Med, Div Nephrol, Med Ctr, Durham, NC 27710 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 50卷 / 06期
关键词：
D O I：
10.1053/j.ajkd.2007.10.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：904 / 907
页数：4
相关论文
共 50 条
  • [1] Tolvaptan, Vasopressin V2 Receptor Antagonist
    Inomata, Takayuki
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S135 - S135
  • [2] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187
  • [3] Tolvaptan.: Treatment of heart failure, vasopressin V2 antagonist.
    Sorbera, LA
    Castañer, J
    Bayés, M
    Silvestre, J
    DRUGS OF THE FUTURE, 2002, 27 (04) : 350 - 357
  • [4] Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure
    Veeraveedu, Punniyakoti T.
    Watanabe, Kenichi
    Ma, Meilei
    Palaniyandi, Suresh S.
    Yamaguchi, Ken'ichi
    Suzuki, Kenji
    Kodama, Makoto
    Aizawa, Yoshifusa
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (10) : 1466 - 1475
  • [5] Vasopressin V2 Receptor Antagonist Tolvaptan is Effective in Heart Failure Patients With Reduced Cardiac Systolic Function
    Suzuki, Satoshi
    Yoshihisa, Akiomi
    Yamaki, Takayoshi
    Sugimoto, Koichi
    Kunii, Hiroyuki
    Nakazato, Kazuhiko
    Abe, Yukihiko
    Saito, Tomiyoshi
    Ohwada, Takayuki
    Saitoh, Shu-ichi
    Kubota, Isao
    Takeishi, Yasuchika
    CIRCULATION, 2013, 128 (22)
  • [6] Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure
    Ishikawa, Mayuko
    Kobayashi, Naohiko
    Sugiyama, Fumihiro
    Onoda, Sho
    Ishimitsu, Toshihiko
    INTERNATIONAL HEART JOURNAL, 2013, 54 (02) : 98 - 106
  • [7] V2 receptor antagonism with tolvaptan in heart failure
    Costello-Boerrigter, Lisa C.
    Boerrigter, Guido
    Burnett, John C., Jr.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (10) : 1639 - 1647
  • [8] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +
  • [9] Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema
    Hiramine, Yasunari
    Uto, Hirofumi
    Imamura, Yasushi
    Hiwaki, Takuya
    Kure, Takeshi
    Ijuin, Sho
    Oda, Kohei
    Mawatari, Seiichi
    Kumagai, Kotaro
    Tokunaga, Koki
    Higashi, Hirofumi
    Kanetsuki, Ichiro
    Kubozono, Osamu
    Maenohara, Shigeho
    Ido, Akio
    HEPATOLOGY RESEARCH, 2017, 47 (06) : 542 - 557
  • [10] Three Cases of Tolvaptan, that is Vasopressin V2 Receptor Antagonisut, is Effective of Congestive Heart Failure
    Fujiwara, Syouhei
    Yuba, Masao
    Tateishi, Jun
    Masuyama, Tohru
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S166 - S166
12345